Search results for: Oncology
Filter search results
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…Cancer, 107, 22-35. DOI | PubMed Doble, B., Tan, M., Harris, A., Lorgelly, P. (2015). Modelling companion diagnostics in economic evaluations of targeted oncology therapies: a systematic review and…
OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development
4 October 2016, 11:00pm
…also developed the NICE scientific advice database. Prior to NICE Francois worked for the EMA for 15 years. His activities covered both pre- (registration of centrally authorised products in oncology,…
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
…sharing” approach of the CDF to selected non-oncology drugs. The UK CDF remains the “poster child” for jurisdictions seeking to implement conditional coverage / reimbursement schemes. Risk sharing is the…
Chris Sampson
9 October 2017
…clinical contexts, including diabetes, oncology, sleep, and neonatal care, but his passion is for mental health; Chris is the Lead Convener for IHEA’s Mental Health Economics Special Interest Group. As…
Shaheer Hassan
28 October 2025
…health economic modelling, and developing evidence-based approaches to improve HTA access. He has contributed to market access strategies for innovative oncology therapies, facilitated stakeholder engagement with key opinion leaders and…
Around The World in HTAs: Italy – What’s Next?
20 April 2023
…on Pricing of Medicines Reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023 Jan;41(1):107-117. Russo, P., Marcellusi, A., Zanuzzi, M., et al. Drug Prices and Value of Oncology Drugs in…
Chris Skedgel
15 July 2019
…He has been a Lead Economic Reviewer for the pan-Canadian Oncology Drug Review (pCODR) and the Canadian Common Drug Review (CDR) and has led the development of NICE submissions in…
Priscila Radu
20 September 2021
Priscila has published research on various health economics topics, including changes in HTA methods in several regions, assessment pathways for precision oncology, and regulatory landscape of digital health in the…
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
…be agreed upon, building on learnings from the oncology space. Finally, Oriol addressed the “elephant in the room”: affordability from the payer perspective. He proposed moving away from the Fee…